JP7482488B2 - Ｃｄ１３７とｐｄ－ｌ１に特異的な新規融合タンパク質 - Google Patents

Ｃｄ１３７とｐｄ－ｌ１に特異的な新規融合タンパク質 Download PDF

Info

Publication number
JP7482488B2
JP7482488B2 JP2021529519A JP2021529519A JP7482488B2 JP 7482488 B2 JP7482488 B2 JP 7482488B2 JP 2021529519 A JP2021529519 A JP 2021529519A JP 2021529519 A JP2021529519 A JP 2021529519A JP 7482488 B2 JP7482488 B2 JP 7482488B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
fusion protein
acid sequence
fusion proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021529519A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021533203A5 (https=
JPWO2020025659A5 (https=
JP2021533203A (ja
Inventor
マリーナ パブリドウ
ルシア パッタリーニ
アリックス スカラー－ダヒレル
クリスティーヌ ローテ
シェーン オルヴィル
アイバ ラシダ ベル
マーロン ヒンナー
ジャネット ペペル
Original Assignee
ピエリス ファーマシューティカルズ ゲーエムベーハー
レ ラボラトリエ セルヴィエ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピエリス ファーマシューティカルズ ゲーエムベーハー, レ ラボラトリエ セルヴィエ filed Critical ピエリス ファーマシューティカルズ ゲーエムベーハー
Publication of JP2021533203A publication Critical patent/JP2021533203A/ja
Publication of JP2021533203A5 publication Critical patent/JP2021533203A5/ja
Publication of JPWO2020025659A5 publication Critical patent/JPWO2020025659A5/ja
Application granted granted Critical
Publication of JP7482488B2 publication Critical patent/JP7482488B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021529519A 2018-07-31 2019-07-31 Ｃｄ１３７とｐｄ－ｌ１に特異的な新規融合タンパク質 Active JP7482488B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18186445 2018-07-31
EP18186445.5 2018-07-31
EP18204548.4 2018-11-06
EP18204548 2018-11-06
PCT/EP2019/070596 WO2020025659A1 (en) 2018-07-31 2019-07-31 Novel fusion protein specific for cd137 and pd-l1

Publications (4)

Publication Number Publication Date
JP2021533203A JP2021533203A (ja) 2021-12-02
JP2021533203A5 JP2021533203A5 (https=) 2022-07-28
JPWO2020025659A5 JPWO2020025659A5 (https=) 2022-07-28
JP7482488B2 true JP7482488B2 (ja) 2024-05-14

Family

ID=67480227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529519A Active JP7482488B2 (ja) 2018-07-31 2019-07-31 Ｃｄ１３７とｐｄ－ｌ１に特異的な新規融合タンパク質

Country Status (28)

Country Link
US (1) US20210363257A1 (https=)
EP (2) EP4249064A3 (https=)
JP (1) JP7482488B2 (https=)
KR (1) KR20210040103A (https=)
CN (1) CN112789292A (https=)
AU (1) AU2019315703A1 (https=)
BR (1) BR112020025263A2 (https=)
CA (1) CA3100119A1 (https=)
CL (1) CL2021000207A1 (https=)
CY (1) CY1126148T1 (https=)
DK (1) DK3830120T5 (https=)
ES (1) ES2948717T3 (https=)
FI (1) FI3830120T3 (https=)
HR (1) HRP20230590T2 (https=)
HU (1) HUE062320T2 (https=)
IL (1) IL279541A (https=)
LT (1) LT3830120T (https=)
MD (1) MD3830120T3 (https=)
MX (1) MX2021000401A (https=)
MY (1) MY200710A (https=)
PH (1) PH12021550001A1 (https=)
PL (1) PL3830120T3 (https=)
RS (1) RS64343B9 (https=)
SG (1) SG11202100989UA (https=)
SI (1) SI3830120T1 (https=)
TW (1) TWI837156B (https=)
WO (1) WO2020025659A1 (https=)
ZA (1) ZA202100125B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019388808A1 (en) * 2018-11-29 2021-06-17 Harbour Biomed Therapeutics Limited Anti-PD-L1 antibody preparation
AU2020253034A1 (en) * 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
US11466086B2 (en) 2019-10-11 2022-10-11 Nanjing Leads Biolabs Co., Ltd. Antibodies binding 4-1BB and uses thereof
AU2021285201A1 (en) 2020-06-05 2022-11-24 Pieris Pharmaceuticals Gmbh Multimeric immunomodulator targeting 4-1BB
WO2022082005A1 (en) * 2020-10-16 2022-04-21 Qlsf Biotherapeutics, Inc. Multispecific binding compounds that bind to pd-l1
CA3203718A1 (en) * 2021-01-08 2022-07-14 Jiawang Liu Anti-pd-l1/anti-4-1bb natural antibody structure-like heterodimeric form bispecific antibody and preparation thereof
CN115521379B (zh) * 2021-07-16 2023-12-22 南京吉盛澳玛生物医药有限公司 Pd-1抗体及其用途
CN115677858A (zh) * 2021-07-23 2023-02-03 合肥瀚科迈博生物技术有限公司 一种能够靶向cd137和pd-l1的双特异性抗体的用途
CN114736303A (zh) * 2022-03-17 2022-07-12 英诺湖医药(杭州)有限公司 抗pd-l1和4-1bb的双功能抗体及其医药用途
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
KR20250071257A (ko) * 2022-09-21 2025-05-21 씨젠 인크. Cd137 및 cd228에 특이적인 신규한 융합 단백질
CN116211860B (zh) * 2023-05-10 2023-08-22 细胞生态海河实验室 Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104406A2 (en) 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
WO2016177762A1 (en) 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
WO2016184882A1 (en) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
WO2017123650A2 (en) 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins
WO2017215590A1 (en) 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
CZ298681B6 (cs) 1998-06-08 2007-12-19 F. Hoffmann-La Roche Ag Lécivo pro lécení infekcí chronické hepatitis C
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
KR20170138574A (ko) * 2015-05-04 2017-12-15 피어이스 파마슈티컬즈 게엠베하 항암 융합 폴리펩타이드
JP6432121B2 (ja) * 2016-03-04 2018-12-05 シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド Ｐｄｌ−１抗体、その医薬組成物及びその使用
CN107082812B (zh) * 2017-03-29 2018-11-13 上海科医联创生物科技有限公司 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
KR102678252B1 (ko) * 2017-09-01 2024-06-26 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 재조합 이중특이적 항체
WO2023000675A1 (zh) * 2021-07-23 2023-01-26 安徽安科生物工程（集团）股份有限公司 靶向pd-l1和4-1bb的双特异性抗体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104406A2 (en) 2014-01-13 2015-07-16 Pieris Ag Multi-specific polypeptide useful for localized tumor immunomodulation
WO2016177762A1 (en) 2015-05-04 2016-11-10 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
WO2016184882A1 (en) 2015-05-18 2016-11-24 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
WO2017123650A2 (en) 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific 41bb-binding fusion proteins
WO2017215590A1 (en) 2016-06-13 2017-12-21 I-Mab Anti-pd-l1 antibodies and uses thereof
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HINNER, MJ et al.，Abstract B023: Costimulatory T-cell engagement via a novel bispecific anti-CD137 /anti-HER2 protein based on Anticalin(R) technology，Cancer Immunology Research，2016年，Vol. 4, No. 1，https://cancerimmunolres.aacrjournals.org/content/4/1_Supplement/B023
SILVA, John-Paul et al.，The S228P Mutation Prevents in Vivo and in Vitro IgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation，The Journal of Biological Chemistry，2015年，Vol. 290, No. 9，pp. 5462-5469，DOI: 10.1074/jbc.M114.600973

Also Published As

Publication number Publication date
MD3830120T3 (ro) 2023-11-30
BR112020025263A2 (pt) 2021-03-09
CA3100119A1 (en) 2020-02-06
HUE062320T2 (hu) 2023-10-28
IL279541A (en) 2021-01-31
HRP20230590T2 (hr) 2024-02-16
CL2021000207A1 (es) 2021-08-13
KR20210040103A (ko) 2021-04-12
EP3830120B1 (en) 2023-05-24
RS64343B9 (sr) 2023-11-30
HRP20230590T1 (hr) 2023-09-15
RS64343B1 (sr) 2023-08-31
SG11202100989UA (en) 2021-02-25
CY1126148T1 (el) 2023-11-15
EP3830120A1 (en) 2021-06-09
US20210363257A1 (en) 2021-11-25
EP3830120B9 (en) 2023-08-30
MD3830120T2 (ro) 2023-08-31
WO2020025659A1 (en) 2020-02-06
PH12021550001A1 (en) 2021-09-27
LT3830120T (lt) 2023-07-10
FI3830120T3 (fi) 2023-06-13
DK3830120T3 (da) 2023-06-26
MY200710A (en) 2024-01-12
EP4249064A3 (en) 2023-12-06
JP2021533203A (ja) 2021-12-02
TWI837156B (zh) 2024-04-01
DK3830120T5 (da) 2024-08-19
CN112789292A (zh) 2021-05-11
SI3830120T1 (sl) 2023-10-30
AU2019315703A1 (en) 2020-12-10
EP4249064A2 (en) 2023-09-27
TW202019967A (zh) 2020-06-01
ES2948717T3 (es) 2023-09-18
PL3830120T3 (pl) 2023-10-09
MX2021000401A (es) 2021-03-25
ZA202100125B (en) 2023-06-28

Similar Documents

Publication Publication Date Title
JP7482488B2 (ja) Ｃｄ１３７とｐｄ－ｌ１に特異的な新規融合タンパク質
JP7476219B2 (ja) Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
US20210403516A1 (en) Anti-cancer fusion polypeptide
JP2023527908A (ja) ４－１ｂｂをターゲティングする多量体免疫調節物質
KR20250071257A (ko) Cd137 및 cd228에 특이적인 신규한 융합 단백질
RU2818349C2 (ru) Новый слитый белок, специфичный для cd137 и pd-l1
RU2814653C2 (ru) Новые слитые белки, специфические в отношении cd137 и gpc3
WO2023089079A1 (en) Novel fusion protein specific for ox40 and pd-l1
HK40053668A (en) Novel fusion protein specific for cd137 and pd-l1
EA046634B1 (ru) Новый слитый белок, специфичный к cd137 и pd-l1
HK40044273B (en) Novel fusion protein specific for cd137 and pd-l1
HK40044273A (en) Novel fusion protein specific for cd137 and pd-l1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220720

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231024

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240206

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240419

R150 Certificate of patent or registration of utility model

Ref document number: 7482488

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150